{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:28:55Z","timestamp":1784824135350,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Finnish Cancer Foundation","award":["1"],"award-info":[{"award-number":["1"]}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["1"],"award-info":[{"award-number":["1"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"crossref","award":["1"],"award-info":[{"award-number":["1"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"crossref","award":["1"],"award-info":[{"award-number":["1"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["1"],"award-info":[{"award-number":["1"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["1"],"award-info":[{"award-number":["1"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["1"],"award-info":[{"award-number":["1"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune suppressing molecule CD73 is overexpressed in various cancers and associated with poor survival. Little is so far known about the predictive value of CD73 in pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to investigate the prognostic significance of CD73 in PDAC. The study material consisted of 110 radically treated patients for PDAC. Tissue microarray blocks were constructed and stained immunohistochemically using CD73 antibody. Staining intensity and numbers of stained tumour cells, inflammatory cells, stroma, and blood vessels were assessed. High-level CD73 expression in tumour cells was positively associated with PD-L1 expression, perineural invasion, and histopathological grade. CD73 positivity in tumour-infiltrating lymphocytes was significantly associated with lymph node metastasis. Lymphocytic CD73 positivity was also associated with staining positivity in both stroma and vascular structures. In addition, CD73 positivity in vascular structures and stroma were associated with each other. There were no significant associations between CD73 positive tumour cells and CD73 positivity in any other cell types. PD-L1 expression was associated with CD73 staining positivity in stroma (<jats:italic>p<\/jats:italic>\u2009=\u20090.007) and also with histopathological grade (<jats:italic>p<\/jats:italic>\u2009=\u20090.033) and T class (<jats:italic>p<\/jats:italic>\u2009=\u20090.016) of the primary tumour. CD73 positivity in tumour cells was significantly associated with poor disease-specific (<jats:italic>p<\/jats:italic>\u2009=\u20090.021) and overall survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.016). In multivariate analysis, CD73 positivity in tumour cells was an independent negative prognostic factor together with histopathological grade, TNM stage, and low immune cell score. In conclusion, high CD73 expression in tumour cells is associated with poor survival in PDAC independently of the number of tumour-infiltrating lymphocytes or TNM stage.<\/jats:p>","DOI":"10.1007\/s00428-020-02888-4","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T11:02:50Z","timestamp":1594897370000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer"],"prefix":"10.1007","volume":"478","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-5690","authenticated-orcid":false,"given":"Ky\u00f6sti","family":"Tahkola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit","family":"Ahtiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilmo","family":"Kellokumpu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka-Pekka","family":"Mecklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Laukkarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joni","family":"Laakkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Kenessey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Salmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"2888_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ceb.2015.06.004","volume":"36","author":"AG Clark","year":"2015","unstructured":"Clark AG, Vignjevic DM (2015) Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol 36:13\u201322. https:\/\/doi.org\/10.1016\/j.ceb.2015.06.004","journal-title":"Curr Opin Cell Biol"},{"key":"2888_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"2888_CR3","first-page":"1016","volume":"7","author":"YA Fouad","year":"2017","unstructured":"Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7:1016\u20131036","journal-title":"Am J Cancer Res"},{"key":"2888_CR4","doi-asserted-by":"publisher","first-page":"608406","DOI":"10.1155\/2012\/608406","volume":"2012","author":"V Chew","year":"2012","unstructured":"Chew V, Toh HC, Abastado J-P (2012) Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol 2012:608406\u2013608410. https:\/\/doi.org\/10.1155\/2012\/608406","journal-title":"J Oncol"},{"key":"2888_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.coi.2010.12.011","volume":"23","author":"WH Fridman","year":"2011","unstructured":"Fridman WH, Mlecnik B, Bindea G et al (2011) Immunosurveillance in human non-viral cancers. Curr Opin Immunol 23:272\u2013278. https:\/\/doi.org\/10.1016\/j.coi.2010.12.011","journal-title":"Curr Opin Immunol"},{"key":"2888_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860\u2013867. https:\/\/doi.org\/10.1038\/nature01322","journal-title":"Nature"},{"key":"2888_CR7","doi-asserted-by":"publisher","unstructured":"Tahkola K, Mecklin J-P, Wirta E-V, Ahtiainen M, Helminen O, B\u00f6hm J, Kellokumpu I (2018) High immune cell score predicts improved survival in pancreatic cancer. Virchows Arch 472. https:\/\/doi.org\/10.1007\/s00428-018-2297-1","DOI":"10.1007\/s00428-018-2297-1"},{"key":"2888_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev 12:298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245","journal-title":"Nat Rev"},{"key":"2888_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/cjp2.71","volume":"3","author":"EV Wirta","year":"2017","unstructured":"Wirta EV, Seppala T, Friman M et al (2017) Immunoscore in mismatch repair-proficient and -deficient colon cancer. J Pathol Res 3:203\u2013213. https:\/\/doi.org\/10.1002\/cjp2.71","journal-title":"J Pathol Res"},{"key":"2888_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","volume":"4","author":"C Fitzmaurice","year":"2018","unstructured":"Fitzmaurice C, Akinyemiju TF, Al Lami FH et al (2018) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 4:1553\u20131568. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2706","journal-title":"JAMA Oncol"},{"key":"2888_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","volume":"363","author":"D Li","year":"2004","unstructured":"Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet (London, England) 363:1049\u20131057. https:\/\/doi.org\/10.1016\/S0140-6736(04)15841-8","journal-title":"Lancet (London, England)"},{"key":"2888_CR12","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1200\/JCO.2016.67.5553","volume":"34","author":"AA Khorana","year":"2016","unstructured":"Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MHG (2016) Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 34:2541\u20132556. https:\/\/doi.org\/10.1200\/JCO.2016.67.5553","journal-title":"J Clin Oncol"},{"key":"2888_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00262-018-2290-1","volume":"68","author":"A Sciarra","year":"2019","unstructured":"Sciarra A, Monteiro I, Menetrier-Caux C et al (2019) CD73 expression in normal and pathological human hepatobiliopancreatic tissues. Cancer Immunol Immunother 68:467\u2013478. https:\/\/doi.org\/10.1007\/s00262-018-2290-1","journal-title":"Cancer Immunol Immunother"},{"key":"2888_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","volume":"19","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Pacher P, Vizi ES, Hasko G (2013) CD39 and CD73 in immunity and inflammation. Trends Mol Med 19:355\u2013367. https:\/\/doi.org\/10.1016\/j.molmed.2013.03.005","journal-title":"Trends Mol Med"},{"key":"2888_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2217\/imt.15.106","volume":"8","author":"D Allard","year":"2016","unstructured":"Allard D, Allard B, Gaudreau P-O, Chrobak P, Stagg J (2016) CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy 8:145\u2013163. https:\/\/doi.org\/10.2217\/imt.15.106","journal-title":"Immunotherapy"},{"key":"2888_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12885-018-4073-7","volume":"18","author":"T Jiang","year":"2018","unstructured":"Jiang T, Xu X, Qiao M, Li X, Zhao C, Zhou F, Gao G, Wu F, Chen X, Su C, Ren S, Zhai C, Zhou C (2018) Comprehensive evaluation of NT5E\/CD73 expression and its prognostic significance in distinct types of cancers. BMC Cancer 18:267. https:\/\/doi.org\/10.1186\/s12885-018-4073-7","journal-title":"BMC Cancer"},{"key":"2888_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12885-017-3128-5","volume":"17","author":"Z-W Gao","year":"2017","unstructured":"Gao Z-W, Wang H-P, Lin F, Wang X, Long M, Zhang HZ, Dong K (2017) CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity. BMC Cancer 17:135. https:\/\/doi.org\/10.1186\/s12885-017-3128-5","journal-title":"BMC Cancer"},{"key":"2888_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0303-7207(03)00197-7","volume":"205","author":"MR Wink","year":"2003","unstructured":"Wink MR, Tamajusuku ASK, Braganhol E, Casali EA, Barreto-Chaves MLM, Sarkis JJF, Battastini AMO (2003) Thyroid hormone upregulates ecto-5\u2032-nucleotidase\/CD73 in C6 rat glioma cells. Mol Cell Endocrinol 205:107\u2013114","journal-title":"Mol Cell Endocrinol"},{"key":"2888_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/01.cmr.0000215030.69823.11","volume":"16","author":"R Sadej","year":"2006","unstructured":"Sadej R, Spychala J, Skladanowski AC (2006) Expression of ecto-5\u2032-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res 16:213\u2013222. https:\/\/doi.org\/10.1097\/01.cmr.0000215030.69823.11","journal-title":"Melanoma Res"},{"key":"2888_CR20","first-page":"1341","volume":"17","author":"X Zhou","year":"2007","unstructured":"Zhou X, Zhi X, Zhou P et al (2007) Effects of ecto-5\u2032-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep 17:1341\u20131346","journal-title":"Oncol Rep"},{"key":"2888_CR21","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1365-2559.2005.02277.x","volume":"48","author":"T Kondo","year":"2006","unstructured":"Kondo T, Nakazawa T, Murata S-I, Katoh R (2006) Expression of CD73 and its ecto-5\u2032-nucleotidase activity are elevated in papillary thyroid carcinomas. Histopathology 48:612\u2013614","journal-title":"Histopathology"},{"key":"2888_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/jso.23056","volume":"106","author":"XR Wu","year":"2012","unstructured":"Wu XR, He XS, Chen YF et al (2012) High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol 106:130\u2013137. https:\/\/doi.org\/10.1002\/jso.23056","journal-title":"J Surg Oncol"},{"key":"2888_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.urolonc.2009.01.035","volume":"28","author":"J Stella","year":"2010","unstructured":"Stella J, Bavaresco L, Braganhol E, Rockenbach L, Farias PF, Wink MR, Azambuja AA, Barrios CH, Morrone FB, Oliveira Battastini AM (2010) Differential ectonucleotidase expression in human bladder cancer cell lines. Urol Oncol 28:260\u2013267. https:\/\/doi.org\/10.1016\/j.urolonc.2009.01.035","journal-title":"Urol Oncol"},{"key":"2888_CR24","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00262-011-1040-4","volume":"60","author":"SFM Hausler","year":"2011","unstructured":"Hausler SFM, Montalban del Barrio I, Strohschein J et al (2011) Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 60:1405\u20131418. https:\/\/doi.org\/10.1007\/s00262-011-1040-4","journal-title":"Cancer Immunol Immunother"},{"key":"2888_CR25","doi-asserted-by":"publisher","first-page":"57327","DOI":"10.18632\/oncotarget.16905","volume":"8","author":"R Wang","year":"2017","unstructured":"Wang R, Zhang Y, Lin X et al (2017) Prognositic value of CD73-adenosinergic pathway in solid tumor: a meta-analysis and systematic review. Oncotarget 8:57327\u201357336. https:\/\/doi.org\/10.18632\/oncotarget.16905","journal-title":"Oncotarget"},{"key":"2888_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/carcin\/bgy154","volume":"40","author":"MK Koivisto","year":"2019","unstructured":"Koivisto MK, Tervahartiala M, Kenessey I, Jalkanen S, Bostr\u00f6m PJ, Salmi M (2019) Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis 40:84\u201392. https:\/\/doi.org\/10.1093\/carcin\/bgy154","journal-title":"Carcinogenesis"},{"key":"2888_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00109-018-01742-0","volume":"97","author":"L Zhou","year":"2019","unstructured":"Zhou L, Jia S, Chen Y, Wang W, Wu Z, Yu W, Zhang M, Ding G, Cao L (2019) The distinct role of CD73 in the progression of pancreatic cancer. J Mol Med (Berl) 97:803\u2013815. https:\/\/doi.org\/10.1007\/s00109-018-01742-0","journal-title":"J Mol Med (Berl)"},{"key":"2888_CR28","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.2147\/OTT.S146383","volume":"10","author":"Y Zhuan-Sun","year":"2017","unstructured":"Zhuan-Sun Y, Huang F, Feng M, Zhao X, Chen W, Zhu Z, Zhang S (2017) Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis. Onco Targets Ther 10:5005\u20135012. https:\/\/doi.org\/10.2147\/OTT.S146383","journal-title":"Onco Targets Ther"},{"key":"2888_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","volume":"93","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W et al (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387\u2013391. https:\/\/doi.org\/10.1038\/sj.bjc.6602678","journal-title":"Br J Cancer"},{"key":"2888_CR30","volume-title":"Trotti A editors: AJCC cancer staging manual","author":"SB Edge","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC et al (2010) Trotti A editors: AJCC cancer staging manual. Springer, New York"},{"key":"2888_CR31","unstructured":"Bosman FT, Carneiro F, Hruban RHTN (2010) WHO classification of tumours of the digestive system. WHO"},{"key":"2888_CR32","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1158\/0008-5472.CAN-10-4246","volume":"71","author":"J Stagg","year":"2011","unstructured":"Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MWL, Darcy PK, Smyth MJ (2011) CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71:2892\u20132900. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-4246","journal-title":"Cancer Res"},{"key":"2888_CR33","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/ijc.31534","volume":"143","author":"W-W Deng","year":"2018","unstructured":"Deng W-W, Li Y-C, Ma S-R, Mao L, Yu GT, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ (2018) Specific blockade CD73 alters the \u201cexhausted\u201d phenotype of T cells in head and neck squamous cell carcinoma. Int J Cancer 143:1494\u20131504. https:\/\/doi.org\/10.1002\/ijc.31534","journal-title":"Int J Cancer"},{"key":"2888_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.suronc.2017.01.007","volume":"26","author":"S Schorn","year":"2017","unstructured":"Schorn S, Demir IE, Haller B, Scheufele F, Reyes CM, Tieftrunk E, Sargut M, Goess R, Friess H, Ceyhan GO (2017) The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - a systematic review and meta-analysis. Surg Oncol 26:105\u2013115. https:\/\/doi.org\/10.1016\/j.suronc.2017.01.007","journal-title":"Surg Oncol"},{"key":"2888_CR35","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.3892\/ol.2017.7569","volume":"15","author":"K Ono","year":"2018","unstructured":"Ono K, Shiozawa E, Ohike N, Fujii T, Shibata H, Kitajima T, Fujimasa K, Okamoto N, Kawaguchi Y, Nagumo T, Tazawa S, Homma M, Yamochi\u2011Onizuka T, Norose T, Yoshida H, Murakami M, Tate G, Takimoto M (2018) Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: a retrospective study of 136 patients. Oncol Lett 15:2123\u20132130. https:\/\/doi.org\/10.3892\/ol.2017.7569","journal-title":"Oncol Lett"},{"key":"2888_CR36","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","volume":"19","author":"B Allard","year":"2013","unstructured":"Allard B, Pommey S, Smyth MJ, Stagg J (2013) Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19:5626\u20135635. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0545","journal-title":"Clin Cancer Res"},{"key":"2888_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK (2015) Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 3:506\u2013517. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0211","journal-title":"Cancer Immunol Res"},{"key":"2888_CR38","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1074\/jbc.M109.047423","volume":"285","author":"M Mandapathil","year":"2010","unstructured":"Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL (2010) Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 285:7176\u20137186. https:\/\/doi.org\/10.1074\/jbc.M109.047423","journal-title":"J Biol Chem"},{"key":"2888_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.immuni.2011.12.019","volume":"36","author":"F Chalmin","year":"2012","unstructured":"Chalmin F, Mignot G, Bruchard M, Chevriaux A, V\u00e9gran F, Hichami A, Ladoire S, Derang\u00e8re V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, Apetoh L, R\u00e9b\u00e9 C, Ghiringhelli F (2012) Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 36:362\u2013373. https:\/\/doi.org\/10.1016\/j.immuni.2011.12.019","journal-title":"Immunity"},{"key":"2888_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41467-018-08123-8","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen S, Fan J, Zhang M, Qin L, Dominguez D, Long A, Wang G, Ma R, Li H, Zhang Y, Fang D, Sosman J, Zhang B (2019) CD73 expression on effector T cells sustained by TGF-beta facilitates tumor resistance to anti-4-1BB\/CD137 therapy. Nat Commun 10:150. https:\/\/doi.org\/10.1038\/s41467-018-08123-8","journal-title":"Nat Commun"},{"key":"2888_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-017-0665-0","volume":"16","author":"S-R Ma","year":"2017","unstructured":"Ma S-R, Deng W-W, Liu J-F, Mao L, Yu GT, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ (2017) Blockade of adenosine A2A receptor enhances CD8(+) T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol Cancer 16:99. https:\/\/doi.org\/10.1186\/s12943-017-0665-0","journal-title":"Mol Cancer"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02888-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-020-02888-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02888-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T23:55:14Z","timestamp":1626393314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-020-02888-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2888"],"URL":"https:\/\/doi.org\/10.1007\/s00428-020-02888-4","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"27 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The use of patient samples and the data inquiry were approved by the Oulu University Hospital Ethics Committee. The need to obtain written or oral consent from patients to use their samples in research was waived by the Finnish National Authority for Medicolegal Affairs (VALVIRA, Dnro 10832\/06.01.03.01\/2014).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}